Featured Research

from universities, journals, and other organizations

Zinc Linked To Macular Degeneration, Study Suggests

Date:
August 28, 2007
Source:
George Mason University
Summary:
The mineral zinc could play a role in the development of macular degeneration. In studying eye tissue samples, the researchers found that deposits, that are hallmarks of age-related macular degeneration, contain large amounts of zinc. This finding might be particularly important because zinc supplements are widely given to patients to help boost weak immune systems.

A team of scientists, including three researchers at George Mason University, found that the mineral zinc could play a role in the development of macular degeneration. In studying eye tissue samples, the researches found that deposits, that are hallmarks of age-related macular degeneration (AMD), contain large amounts of zinc.

This finding, published in the journal Experimental Eye Research, might be particularly important because zinc supplements are widely given to patients to help boost weak immune systems. In addition, a 2001 study from the National Eye Institute found that high doses of zinc supplements, combined with antioxidants, may postpone the progression to blindness.

AMD is a medical condition in which the macula, the place of central vision in the eye, experiences atrophy and in some cases bleeding. It is the primary cause of blindness in the elderly in Western society and approximately 13 million Americans suffer from the disease according to AMD Alliance International.

“Because earlier findings have shown that that zinc contributes to deposit formation in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, we were prompted to test the theory that zinc might be involved in deposit formation in AMD,” said Mason professor of psychology, Jane Flinn.

“The double-edged sword is that zinc has been found to enhance the immune system, but also could play a role in the advancement of macular degeneration,” said Imre Lengyel of the UCL Institute of Ophthalmology in London, who led the collaborative study.

“We now know that we need to take a closer look at the role zinc plays in the development of AMD,” said Mason graduate psychology student Katherine Cano. “We believe this finding will help us unlock other answers to the mystery of treating this disease.”

The team hopes their findings can be useful in the development of new treatments as well as a more informed approach to zinc intake recommendations.

The study was supported by the Moorfields Eye Hospital Special Trustees and Mercer Fund, a U.S. Department of Energy grant and a Wilkins AMD fund grant.


Story Source:

The above story is based on materials provided by George Mason University. Note: Materials may be edited for content and length.


Cite This Page:

George Mason University. "Zinc Linked To Macular Degeneration, Study Suggests." ScienceDaily. ScienceDaily, 28 August 2007. <www.sciencedaily.com/releases/2007/08/070827143203.htm>.
George Mason University. (2007, August 28). Zinc Linked To Macular Degeneration, Study Suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/08/070827143203.htm
George Mason University. "Zinc Linked To Macular Degeneration, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/08/070827143203.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins